PT  - JOURNAL ARTICLE
AU  - Makkar, Raj R.
TI  - PARTNER Cohort B: TAVI Superior to Standard Therapy at Two Years
DP  - 2011  01
TA  - MD Conference Express
PG  - 5--6
VI  - 11
IP  - 14
4099  - http://mdc.sagepub.com/content/11/14/5.2.short
4100  - http://mdc.sagepub.com/content/11/14/5.2.full
AB  - Transcatheter aortic valve implantation (TAVI) is the recommended treatment for “inoperable” patients with severe aortic stenosis, based on the 1-year results of the PARTNER trial [NCT00530894; Leon MB et al. N Engl J Med 2010]. The objective of this PARTNER trial analysis was to evaluate the clinical outcomes of TAVI compared with standard therapy at 2 years in patients with inoperable AS [PARTNER Cohort B].